A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)

NCT06181591 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Overactive Bladder

Interventions

DRUG: Mirabegron 50 MG
DRUG: Oxybutynin Chloride 5 MG

Sponsor

Seoul National University Hospital

Collaborators

[object Object]